ancremonam (BOS-228)
/ Boston Pharma, Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 23, 2026
New-generation antibiotics and non-antibiotic strategies against carbapenemase-producing Enterobacterales: More focus on metallo-β-lactamase producers.
(PubMed, Int J Antimicrob Agents)
- "Continued monitoring of resistance trends and the development of innovative therapeutic strategies is warranted in the ongoing battle against CPE harboring blaMBL."
Journal • Review • Infectious Disease
1 to 1
Of
1
Go to page
1